A phase II randomized trial in patients with recurrent endometrial cancer previously treated with platinum-based chemotherapy evaluated durvalumab alone or in combination with tremelimumab (an anti-CTLA-4 agent) [46]. The gene discussed is CTLA4; the disease is endometrial cancer.